CTRI/2021/01/030238Not yet recruitingPhase 2
AN OPEN LABEL DOUBLE ARM RANDOMIZED CONTROLLED CLINICAL STUDY TO EVALUATE THE EFFICACY OF PATHADI CHURNA INDADRU(TINEA)
Dean Faculty of Ayurved Parul University0 sites0 target enrollmentStarted: TBDLast updated:
Trial Snapshot
- Phase
- Phase 2
- Status
- Not yet recruiting
- Sponsor
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
Inclusion Criteria
- •Patients having clinical signs like kandu, raga, mandala, pidika.
- •Patients of all varieties of Tinea will be included irrespective of area of infection. Viz., Tinea â??corporis, crusis, capitis, pedis,
- •manuum, except tinea unguium, tinea barbae .
- •Chronicity not more than 1 year.
Exclusion Criteria
- •patient having Tinea unginum, tinea barbae.
- •K/C/o Uncontrolled Hypertension & Diabetes Melitus.
- •Pregnant and lactating Women.
- •k/c/o of immunocompromised subjects & autoimmune cases.
Investigators
Similar Trials
Active, not recruiting
Not Applicable
Studying kidney function in patients with a kidney transplant treated with anti-rejection therapy based on Advagraf when used with or without sirolimus.Prophylaxis of rejection in kidney allograft recipients (by immunosuppression)MedDRA version: 13.1Level: LLTClassification code 10050436Term: Prophylaxis against renal transplant rejectionSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2010-019639-37-NLAstellas Pharma Europe Ltd.772
Active, not recruiting
Not Applicable
Studying kidney function in patients with a kidney transplant treated with anti-rejection therapy based on Advagraf when used with or without sirolimus.Prophylaxis of rejection in kidney allograft recipients (by immunosuppression)MedDRA version: 14.0Level: LLTClassification code 10050436Term: Prophylaxis against renal transplant rejectionSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2010-019639-37-CZAstellas Pharma Europe Ltd.772
Active, not recruiting
Not Applicable
A MULTICENTER, TWO ARM, RANDOMIZED, OPEN LABEL CLINICAL STUDY INVESTIGATING RENAL FUNCTION IN AN ADVAGRAF-BASED IMMUNOSUPPRESSIVE REGIMEN WITH OR WITHOUT SIROLIMUS IN KIDNEY TRANSPLANT SUBJECTS. - ADHEREProphylaxis of rejection in kidney allograft recipients (by immunosuppression)MedDRA version: 12.1Level: LLTClassification code 10050436Term: Prophylaxis against renal transplant rejectionEUCTR2010-019639-37-HUAstellas Pharma Europe Ltd.772
Active, not recruiting
Not Applicable
Studying kidney function in patients with a kidney transplant treated with anti-rejection therapy based on Advagraf when used with or without sirolimus.Prophylaxis of rejection in kidney allograft recipients (by immunosuppression)MedDRA version: 15.1Level: LLTClassification code 10050436Term: Prophylaxis against renal transplant rejectionSystem Organ Class: 100000004865EUCTR2010-019639-37-ATAstellas Pharma Europe Ltd.772
Active, not recruiting
Not Applicable
A MULTICENTER, TWO ARM, RANDOMIZED, OPEN LABEL CLINICAL STUDY TO COMPARE RENAL FUNCTION IN STABLE HEART TRANSPLANT RECIPIENTS RECEIVING AN ADVAGRAF® BASED IMMUNOSUPPRESSIVE REGIMEN WITH OR WITHOUT EVEROLIMUS.ESTUDIO CLÍNICO ABIERTO, MULTICÉNTRICO Y ALEATORIZADO, CON DOS RAMAS DE TRATAMIENTO, PARA COMPARAR LA FUNCIÓN RENAL EN UN RÉGIMEN INMUNOSUPRESOR BASADO EN ADVAGRAF® CON O SIN EVEROLIMUS EN PACIENTES ESTABLES RECEPTORES DE UN TRASPLANTE DE CORAZÓN - ADVANTAGEProphylaxis of heart transplant rejection.Profilaxis del rechazo en trasplante cardiacoMedDRA version: 14.0Level: LLTClassification code 10050432Term: Prophylaxis against heart transplant rejectionSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2010-022941-72-ESAstellas Pharma Europe Ltd.336